Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Inclusion Criteria: * Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow up; procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Genetically confirmed diagnosis of VHL or measurable disease consistent with the clinical diagnosis of VHL * At least one measurable VHL related lesion, which is undergoing surveillance, and patient is not at immediate risk of needing intervention for this or other lesions; biopsy is not required given the known likely etiology and natural history in the setting of a positive genetic test * Brain: asymptomatic hemangioblastoma, \>= 0.5 cm * Spine: asymptomatic hemangioblastoma, \>= 0.5 cm * Renal: solid mass suspicious for renal cell carcinoma (RCC) \>= 1 cm or cystic mass (Bosniak 3-4) \>= 1 cm * Pancreas: solid mass \>= 1 cm and =\< 3 cm suspicious for neuroendocrine tumor, or neuroendocrine tumor \> 3 cm but not considered operable * Eye: asymptomatic peripapillary and/or macular hemangioblastoma, any size * Adrenal: asymptomatic or controlled pheochromocytoma greater than 1 cm in size * Patients may have received prior V…